

1 **TITLE PAGE:**

2 **Title:** Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or  
3 heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis  
4 patients.

5  
6 **Running title:** Humoral response to the Sputnik V and Sputnik V/Moderna in dialysis.

7  
8 **Authors:** Gustavo LAHAM<sup>a</sup>, Alfredo P. MARTÍNEZ<sup>b</sup>, Wanda ROJAS GIMENEZ<sup>a</sup>, Lucas  
9 AMAYA<sup>b</sup>, Anabel ABIB<sup>a</sup>, Natalia ECHEGOYEN<sup>b</sup>, Carlos DÍAZ<sup>a</sup>, Alicia LUCERO<sup>b</sup>, Antonella  
10 MARTELLI<sup>b</sup>, Cristina VIDELA<sup>b</sup>, Karin NEUKAM<sup>c,d\*</sup>, Federico A. DI LELLO<sup>e,f\*</sup>

11  
12 **Affiliations:**

13 <sup>a</sup>Nephrology Section, Department of Medicine, Centro de Educación Médica e Investigaciones  
14 Clínicas Norberto Quirno "CEMIC". Buenos Aires, Argentina.

15 <sup>b</sup>Virology Section, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno  
16 "CEMIC". Buenos Aires, Argentina.

17 <sup>c</sup>Servicio de Enfermedades Infecciosas, UCEIMP. Hospital Universitario Virgen del Rocío.  
18 Seville, Spain.

19 <sup>d</sup>Instituto de Biomedicina de Sevilla/CSIC/Universidad de Sevilla. Seville, Spain.

20 <sup>e</sup>Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones  
21 en Bacteriología y Virología Molecular (IBaViM). Buenos Aires, Argentina.

22 <sup>f</sup>Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires,  
23 Argentina.

24  
25 **\*Corresponding Author:** Dr. Federico Alejandro Di Lello, Facultad de Farmacia y Bioquímica,  
26 Universidad de Buenos Aires, Junín 956, 4º piso, (1113), Ciudad de Buenos Aires, Argentina.

27 E-mail: [fadilello@ffyb.uba.ar](mailto:fadilello@ffyb.uba.ar)

28

29 Dr. Karin Neukam, Servicio de Enfermedades Infecciosas, UCEIMP. Hospital Universitario

30 Virgen del Rocío. Avenida Manuel Siurot s/n. 41013, Seville, Spain and Instituto de Biomedicina

31 de Sevilla/CSIC/Universidad de Sevilla. Seville, Spain.

32 E-mail: [karin.neukam@gmail.com](mailto:karin.neukam@gmail.com)

33

34 **ABSTRACT**

35 **Introduction:** The humoral response to vaccines is the most used tool to evaluate the  
36 protection against SARS-CoV-2 infection. Dialysis patients are a high-risk population and have  
37 a reduced immune response to vaccination.

38 **Objective:** To assess the humoral response to homologous Gam-COVID-Vac (Sputnik V) and  
39 heterologous Sputnik V/mRNA-1273 (Moderna) vaccination in dialysis patients.

40 **Methods:** SARS-CoV-2 anti-spike IgG (RBD) concentration was estimated 3-16 weeks after  
41 complete vaccination. Reactogenicity was evaluated until day 7 by patients' self-reported side  
42 events.

43 **Results:** 107 participants were enrolled [n=84 homologous (SpV/SpV), n=23 heterologous  
44 (SpV/Mod)]. Median (IQR) age was 64 (50-75) years old and 79 (73.8%) were male.  
45 Additionally, 19 (22.6%) of the SpV/SpV and 4 (17.4%) of the SpV/Mod group had a prior  
46 confirmed SARS-CoV-2 infection (p=0.589). In the overall population, 103 patients reached  
47 seroconversion (96.3%). Anti-S-RBD IgG median titers (IQR) were higher in the heterologous  
48 [1222 (288-5680) BAU/mL] than in the homologous scheme [447 (100-1551) BAU/mL],  
49 p=0.022. In a linear model adjusted for age and gender, previous SARS-COV-2 infection (B:  
50 1944.3; CI95: 1136.2-2753.4; p<0.001), and SpV/Mod vaccination scheme (B: 1241.5; CI95:  
51 420.39-2062.6; p=0.003) were independently associated with anti-S-RBD levels. Finally, a  
52 higher frequency of adverse effects was associated with the heterologous scheme, although  
53 they were well tolerated by all individuals.

54 **Conclusion:** The present study provides evidence that the homologous SpV/SpV and  
55 heterologous SpV/Mod schemes showed good efficacy and safety under dialysis conditions.  
56 These results could be useful for future vaccination strategies, especially aimed at this risk  
57 group.

58

59 **Keywords:** Dialysis; SARS-CoV-2; Vaccine; Heterologous scheme; Gam-COVID-Vac; mRNA-  
60 1273

## 61 **INTRODUCTION**

62 Patients under dialysis are at increased risk for severe coronavirus infectious disease 2019  
63 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)  
64 than the general population, with reported mortality rates of up to 28.3% [1-3-]. This situation  
65 mainly obeys to a considerably higher mean patients' age (approximately 65 years old) and the  
66 frequent presence of comorbid conditions such as obesity, diabetes, and high blood pressure  
67 that are linked with a more severe COVID-19 course. Fortunately, effective vaccination  
68 schemes against SARS-CoV-2 inducing reduction of both infection and the risk of severe  
69 COVID-19 have been rapidly developed [4-7-]. Moreover, when facing first dose serious  
70 adverse effects or dose supply shortcomings, introduced heterologous vaccination schemes  
71 have shown promising results [8-12-]. Nevertheless, clinical trials do not provide information  
72 about vaccine efficacy in dialysis populations and possible differences in immunogenicity among  
73 SARS-CoV-2 vaccination schemes are poorly understood due to their novelty. Particularly, the  
74 homologous Gam-COVID-VAC (Sputnik V) and the heterologous vaccination scheme including  
75 Sputnik V as a prime dose and mRNA-1273 (Moderna) as a booster dose have been barely  
76 studied since Sputnik V is not approved in all countries and its implementation suffers  
77 geographic limitations. In Argentina, the National Administration of Medicines, Food, and  
78 Medical Technology (ANMAT) has approved Sputnik V use; however, due to the second dose  
79 shortage, mRNA-1273 (Moderna) has been frequently administered as the booster dose.  
80 In this scenario, the present study aimed to assess the humoral response to homologous  
81 Sputnik V and heterologous Sputnik V/Moderna vaccination in dialysis patients.

82

83

84 **MATERIAL AND METHODS**

85 *Study design and population*

86 From March to October 2021, subjects who attended for hemodialysis at the Centro de  
87 Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC), Buenos Aires,  
88 Argentina, were included in this prospective cohort study. Inclusion criteria were i) patients who  
89 had received Sputnik V prime immunization, ii) they had received a boost dose of either Sputnik  
90 V (SpV/SpV) or Moderna (SpV/Mod) vaccines within 18 weeks post-prime dose, and iii) they  
91 presented to monitor their humoral immune response three weeks after the boost dose. The  
92 vaccination scheme depended on dose availability and the prioritization of risk populations as  
93 established by the Argentine Ministry of Health.

94

95 *Immunogenicity*

96 Binding IgG antibodies against the spike (S) receptor-binding domain (RBD) of SARS-CoV-2  
97 (anti-S-RBD) concentration was assessed at 3-16 weeks after boost. Anti-S-RBD antibodies  
98 were quantified using the Abbott Diagnostics SARS-CoV-2 IgG II Quant chemiluminescent  
99 microparticle immunoassay (CMIA) on an Architect i2000 SR and an Alinity I analyzer (Abbott  
100 Diagnostics, Abbott Park, Illinois, USA). To standardize the results to WHO binding antibody  
101 units (BAU), a correction factor for Abbott arbitrary units (AU) was applied where 1 BAU/mL  
102 equals 0.142 AU, as previously established by Abbott with the WHO international standard  
103 NIBSC 20–136 [13-]. Following the manufacturer’s recommendations, samples were considered  
104 reactive for anti-S-RBD when titers were above 50 AU/mL (7.2 BAU/mL). An 80% protective  
105 effect (PROT-80) against symptomatic SARS-CoV-2 infection was assumed when anti-S-RBD  
106 titers were 506 BAU/ml or higher [14-].

107

108

109

110 *Reactogenicity*

111 All patients were invited to complete an online questionnaire to report all possible post-boost  
112 vaccination adverse events and required medical assistance. The intensity of adverse effects  
113 was graded as mild, moderate, and severe depending on the interference with daily activities.

114

115 *Statistical analysis*

116 Descriptive statistics and univariate analyses were performed. The outcome variable was the  
117 anti-S-RBD titer at least three weeks after the boost dose. Differences in anti-S-RBD levels and  
118 PROT-80 according to demographic and clinical parameters were evaluated. Categorical  
119 variables were expressed as numbers (percentage) and analyzed using the Chi-square test or  
120 the Fisher's test. The student's t-test and the Mann-Whitney *U* test were used to compare  
121 independent continuous variables, expressed as median (interquartile range, IQR). For related  
122 continuous variables, the Wilcoxon signed-rank test was applied. Those factors associated with  
123 anti-S-RBD levels with a  $p < 0.2$  in the univariate analysis, were evaluated in a generalized linear  
124 model adjusted for age and sex. Likewise, multivariate logistic regression models were  
125 developed to identify factors associated with PROT-80. Adjusted odds ratios (AOR) with their  
126 corresponding 95% confidence intervals (CI95) were calculated. Statistical analyses were  
127 carried out using the SPSS statistical software package release 23.0 (IBM SPSS Inc., Chicago,  
128 IL, USA).

129

130 *Ethical Approval and Informed Consent*

131 The study was designed and performed according to the Helsinki declaration and all participants  
132 gave their written informed consent (Study protocol EX-2021-06438339-UBA DME#SSA\_FFYB,  
133 Ethics committee of the Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires).

134

135

## 136 RESULTS

### 137 *Study population*

138 A total of 107 subjects were included in the study, 84 (78.5%) received SpV/SpV, and the  
139 remaining 23 (21.5%) the SpV/Mod scheme. Seventy-nine (73.8%) participants were male, and  
140 the median (IQR) age was 64 (50-75) years old. Overall, median time intervals were 91 (77-116)  
141 days from prime to boost dose ( $\Delta$ P-B) and 32 (24-47) days from the boost dose to the anti-S-  
142 RBD IgG serological determination ( $\Delta$ B-antiSRBD). Eighty-four (78.5%) individuals were *naïve*  
143 to SARS-CoV-2 infection at the time of prime vaccination. Then, 19 (22.6%) of those who  
144 received the SpV/SpV scheme and 4 (17.4%) who received the SpV/Mod one had a prior  
145 confirmed SARS-CoV-2 infection ( $p=0.589$ ). Table 1 shows detailed characteristics of the study  
146 population.

147

### 148 *Immunogenicity*

149 In the overall population, anti-S-RBD IgG was reactive in 103 (96.3%) persons, 80 (95.2%)  
150 immunized with the SpV/SpV vaccine, and 23 (100%) with the SpV/Mod one ( $p=0.286$ ). Median  
151 (IQR) anti-S-RBD titers were 42.5 (4-1297) BAU/mL after the first dose and 502 (110-1993)  
152 BAU/mL after the boost dose ( $p<0.001$ ). In participants with a confirmed SARS-CoV-2 infection  
153 before vaccination receiving the SpV/SpV scheme, the humoral response as measured by anti-  
154 S-RBD levels was 6.5-fold higher than that observed in *naïve* ones. Similarly, people with a  
155 confirmed SARS-CoV-2 infection before the SpV/Mod scheme administration presented 11-fold  
156 higher anti-S-RBD levels when compared to participants without prior infection (Figure 1). Anti-  
157 S-RBD levels according to epidemiological and clinical parameters are shown in Table 2.  
158 Previous COVID-19 (B: 1944.3; CI95: 1136.2-2753.4;  $p<0.001$ ) and SpV/Mod vaccination  
159 scheme (B:1241.5; CI95: 420.39-2062.6;  $p=0.003$ ) were independently associated with anti-S-  
160 RBD levels in a linear model adjusted for age (B:-1.297; CI05: -23.20-20.61;  $p=0.907$ ), sex (B:-

161 371.92; 95CI -1131.5-387.66; p=0.334),  $\Delta$ P-B (B:54.911; 95CI: -36.641-146.46; p=0.237), and  
162  $\Delta$ B-antiSRB (B:-7.828; CI95: -107.04-91.383; p=0.876).

163  
164 A total of 53 (49.5%) individuals achieved PROT-80. Among participants without prior COVID-  
165 19 who received SpV/SpV or SpV/Mod and those with confirmed COVID-19 who received the  
166 homologous and the heterologous schemes, PROT-80 rates were 36.9%, 57.9%, 73.7%, and  
167 100% ( $p_{\text{linear association}} < 0.001$ ), respectively. Corresponding values according to epidemiological  
168 and clinical parameters are displayed in Table 2. In the multivariate analysis, an independent  
169 association with PROT-80 was observed for prior COVID-19 (AOR: 8.663; CI95: 2.541-29.540;  
170 p=0.001), a heterologous vaccination scheme (AOR: 3.767; CI95: 1.229-10.921; p=0.015) and  
171 age (AOR: 0.962; CI95: 0.933-0.992; p=0.012), in a model adjusted for these parameters, as  
172 well as sex (AOR: 0.883; CI95: 0.331-2.361; p=0.805).

173  
174 *Reactogenicity*

175 The homologous and heterologous immunization schemes were well tolerated, and no medical  
176 assistance or potentially fatal events were reported. Adverse events, including local and  
177 systemic symptoms, were higher for SpV/Mod (47.6%) than for SpV/SpV (23.7%) schemes,  
178 p=0.031. In general, the most frequent systemic adverse events were fatigue (9.9%), myalgia  
179 (5.9%), and fever (2.0%). No patients reported headaches, chills, nausea/vomiting, arthralgia, or  
180 diarrhea. The heterologous vaccine scheme tends to induce more systemic adverse effects than  
181 the homologous one (28.6% vs 15.0%, p=0.148). Regarding local adverse events, pain at the  
182 injection site was reported by 11 patients (10.9%) and tended to be more frequent for the  
183 heterologous scheme than for the homologous one (19.0% vs 8.8%, p=0.178). Figure 2 shows  
184 the reactogenicity by adverse effects (local and systemic) according to the vaccination scheme.

185

186 **DISCUSSION**

187 The present work shows that the implementation of SpV/SpV or SpV/Mod vaccination schemes  
188 against SARS-CoV-2 in patients under dialysis was effective leading to a seroconversion rate of  
189 96.3%. Overall, the heterologous scheme showed an anti-S-RBD level almost 3-fold higher than  
190 the homologous one. Moreover, both vaccination schemes were well tolerated, and no medical  
191 assistance was required.

192  
193 To our knowledge, this is the first study on the heterologous scheme including Sputnik V and  
194 Moderna vaccines in *naïve* and previously SARS-CoV-2 infected patients under dialysis  
195 conditions. Additionally, the study allowed results comparison with the homologous SpV/SpV  
196 scheme. The seroconversion rate of our population under dialysis was similar to that reported  
197 by previous studies showing values between 80-98% [15-20-]. Rosa-Diez (2021) detected a  
198 98% seroconversion rate in a study including 102 dialysis patients vaccinated with the Sputnik V  
199 scheme [16-]. On the other hand, studies performed on patients under dialysis conditions  
200 immunized with Moderna vaccines have shown seroconversion rates ranging between 95% and  
201 97.9% [15-,18-,21-]. Recent evidence suggested that the mRNA vaccine has a better humoral  
202 response when compared to adenovirus-based vaccines [8-,9-,22-24-]. In fact, the higher anti-S-  
203 RBD titer achieved in this study with the SpV/Mod group agrees with previous works performed  
204 on the general population [12-26-]. In this context, our results support the use of Sputnik V or its  
205 combination with the Moderna vaccine as an alternative for dialysis patients. However,  
206 additional studies are necessary to assess the cellular response since the combination of  
207 vaccines appears to enhance the characteristic immune response generated by each  
208 vaccination scheme [22-,27-].

209 Results from our study showed the development of a strong humoral response in the dialysis  
210 setting, even when some works have shown that patients under dialysis present a lower  
211 seroconversion rate and anti-S-RBD titers than healthy controls [28-].

212

213 Regarding PROT-80, almost 50% of the studied population achieved this threshold while  
214 heterologous scheme and prior SARS-CoV-2 infection were associated with higher PROT-80  
215 proportions. Furthermore, the multivariate analysis showed that the 80% vaccine efficacy was  
216 not associated with age, gender,  $\Delta P$ -B, and  $\Delta B$ -antiSRBD. Obtained results were in accordance  
217 with our previous work performed on general population immunized with the SpV/SpV and  
218 SpV/MOD schemes [12-].

219 In the present study, there were no anti-S-RBD IgG significant differences between genders.  
220 These findings are consistent with several studies showing that gender seems not to influence  
221 anti-S-RBD IgG titers achieved with both analyzed vaccine schemes [28-32-].

222

223 No anti-S-RBD IgG difference according to the age of dialyzed patients was observed in our  
224 sample. Available data on the relationship between age and response to vaccines are scarce  
225 and controversial [30-,32-34-]; importantly, older ages were associated with lower rates of  
226 PROT-80. More studies on this issue are warranted as most reports analyzing the age-  
227 associated responses are conducted in healthy populations [30-,32-34-].

228

229 Regarding previous infection with SARS-CoV-2, a significant correlation was found between  
230 higher anti-S-RBD IgG titers and a confirmed past infection for both the SpV/SpV and SpV/MOD  
231 schemes, with a notable difference (11 times) for the heterologous scheme. This finding is in  
232 accordance with our previously reported values for the same vaccination schemes [12-], for the  
233 sputnik V homologous scheme [29-30-] and for RNAm vaccines [35-].

234

235 Additionally, the current study found that the body mass index, time on dialysis, weekly total  
236 Kt/V, as well as other evaluated laboratory parameters showed no association with Anti-S-RBD

237 or PROT-80 levels. There are previous contradictory results regarding this issue. While some  
238 authors, as we did, could not find an association between these variables and the anti-S-RBD  
239 IgG titers [36-], other studies suggest that less comorbidity presence leads to a higher anti-S-  
240 RBD IgG titer [37-38-].

241  
242 There is little data on SpV/SpV or SpV/Mod reactogenicity under dialysis conditions and this  
243 work offers a contribution to the understanding of SARS-CoV-2 vaccination in this setting. In our  
244 sample, adverse events including local and systemic symptoms were higher in dialyzed patients  
245 who received the SpV/Mod scheme as we have previously described for the general population  
246 [12-]. In agreement with other studies, fatigue and myalgia were the most frequent systemic  
247 reactions [12-,39-]. The higher trend in the rate of adverse events in the SpV/Mod group was  
248 expected since it is well proven that stronger side effects were associated with mRNA vaccines  
249 in the general population [11-,12-27-40-,41-]. It is important to note that the frequency of adverse  
250 events was lower than that observed in the general population and no patients required medical  
251 support [12-]. However, the median age of the sample analyzed in the present work was higher  
252 and the effect of age on reactogenicity has already been described in previous studies [4-,5-,42-  
253 ]. Moreover, in a Polewska's (2021) study, adverse events were less frequently observed in  
254 dialyzed patients than in the age and sex-matched control group [39-].

255  
256 This study has a limitation. It should be considered that serious adverse effects have been  
257 reported in a very low frequency and the small size of the analyzed sample might have  
258 influenced this aspect.

259  
260 In conclusion, both analyzed vaccine schemes were immunogenic and showed a high  
261 seroconversion rate. In addition, a significant correlation was found between higher anti-S-RBD  
262 IgG titers and a confirmed prior infection with SARS-CoV-2 for both schemes. Moreover, the

263 heterologous scheme was also associated with a better humoral response. Finally, local and  
264 systemic adverse effects were scarce and mostly mild, demonstrating that both schemes are  
265 safe and well-tolerated. These findings should promote patients on dialysis to receive these  
266 immunization schemes.

267

## 268 **Contributors and authorship**

269 **FAD, GL and KN:** Study concept and design, analysis, and interpretation of data, drafting of the  
270 manuscript and statistical analysis and study supervision.

271 **WRG, AA, NE, CD, AL, AM and CV:** Acquisition of data, critical revision of the manuscript for  
272 important intellectual content and final approval of the version to be submitted. **APM:** Acquisition  
273 of data, analysis and interpretation of data, critical revision of the manuscript for important  
274 intellectual content and final approval of the version to be submitted.

275

276 **Declaration of Competing Interest:** The authors declare that they have no known competing  
277 financial interests or personal relationships that could have appeared to influence the work  
278 reported in this paper. All authors have approved the final version of the article.

279

## 280 **ACKNOWLEDGMENT**

281 FAD is a member of the National Research Council (CONICET) Research Career Program.  
282 K.N. is the recipient of a Miguel Servet contract by the Instituto de Salud Carlos III (grant  
283 number CPII18/00033). We would like to thank Mrs. Silvina Heisecke, from CEMIC-CONICET,  
284 for the copyediting of the manuscript

285

286 **Funding:** This research did not receive any specific grant from funding agencies in the public,  
287 commercial, or not-for-profit sectors.

288

289 **Conflict of Interest:** The authors have no conflicts of interest to declare.

290 **REFERENCES**

- 291 1- Suleyman G, Fadel RA, Malette KM, et al. Clinical Characteristics and Morbidity  
292 Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. *JAMA*  
293 *Netw Open* 2020; 3 (6): e2012270. doi: 10.1001/jamanetworkopen.2020.12270.PMID:  
294 32543702.
- 295 2- Ozturk S, Turgutalp K, Arici M, et al. Mortality analysis of COVID-19 infection in chronic  
296 kidney disease, haemodialysis and renal transplant patients compared with patients without  
297 kidney disease: a nationwide analysis from Turkey. *Nephrol Dial Transplant* 2020; 35 (12):  
298 2083-2095. doi: 10.1093/ndt/gfaa271.PMID: 33275763.
- 299 3- Hsu CM, Weiner DE, Aweh G, et al. COVID-19 Among US Dialysis Patients: Risk  
300 Factors and Outcomes From a National Dialysis Provider. *Am J Kidney Dis* 2021; 77 (5): 748-  
301 756.e1. doi: 10.1053/j.ajkd.2021.01.003. PMID: 33465417
- 302 4- Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1  
303 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a  
304 single-blind, randomised, controlled, phase 2/3 trial. *Lancet* 2021; 396 (10267): 1979-1993. doi:  
305 10.1016/S0140-6736(20) 32466. PMID: 33220855.
- 306 5- Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-  
307 CoV-2 Vaccine. *N Engl J Med* 2021; 384 (5): 403-416. doi: 10.1056/NEJMoa2035389. PMID:  
308 33378609.
- 309 6- Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA  
310 Covid-19 vaccine. *N Engl J Med* 2020; 383 (27): 2603–2615.
- 311 7- Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26  
312 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a  
313 randomised controlled phase 3 trial in Russia. *Lancet* 2021; 397 (10275), 671–681.  
314 [https://doi.org/10.1016/S0140-6736\(21\)00234-8](https://doi.org/10.1016/S0140-6736(21)00234-8).

- 315 8- Borobia AM, Carcas AJ, Pérez-Olmeda M, et al. Immunogenicity and reactogenicity of  
316 BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label,  
317 randomised, controlled, phase 2 trial. *Lancet* 2021; 398 (10295), 121–130.  
318 [https://doi.org/10.1016/S0140-6736\(21\)01420-3](https://doi.org/10.1016/S0140-6736(21)01420-3).
- 319 9- Fabricius D, Ludwig C, Scholz J, et al. mRNA Vaccines Enhance Neutralizing Immunity  
320 against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects. *Vaccines* 2021;  
321 9 (8), 918. <https://doi.org/10.3390/vaccines9080918>
- 322 10- Hillus D, Schwarz T, Tober-Lau P, et al. Safety, reactogenicity, and immunogenicity of  
323 homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and  
324 BNT162b2: a prospective cohort study. *The Lancet Respiratory medicine* 2021; 9 (11), 1255–  
325 1265. Advance online publication. [https://doi.org/10.1016/S2213-2600\(21\)00357-X](https://doi.org/10.1016/S2213-2600(21)00357-X)
- 326 11- Normark J, Vikström L, Gwon YD, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-  
327 1273 Vaccination. *N Engl J Med* 2021; 385 (11), 1049–1051.  
328 <https://doi.org/10.1056/NEJMc2110716>
- 329 12- Pereson JM, Amaya L, Neukam K, et al. Heterologous Gam-COVID-Vac (Sputnik V) /  
330 mRNA-1273 (Moderna) vaccination induces a stronger humoral response than homologous  
331 Sputnik V in a real-world data analysis. *Clin Microbiol Inf* 2022; in press.27-
- 332 13- Galli C, Daghfal D, Averhoff F. Antibody testing for SARS-CoV-2 infection, quantitative  
333 determination, response to vaccines and viral variability. [https://cdn.pepperapps.io/diagnostics-cms/public/60dcbed551c1ff090981ed95?signature=eyJhbGciOiJIc2kiLCJlbmMiOiJBMTI4Q0JDLUhTMjU2In0..9nFGX43vdCD-Qd2XE-NzdA.e5mgnWdULSy2PGkSwfQ10kEG1UQzLUxIzkdUvU7F1xv06WNo-c47joEI46OgfiQdEoako-TvRI4CwkLYtVIVYRR7v2jcgknBx9SFQIzw-nqvFqHkx\\_WlydBAcl4ZA\\_wEKCPydLqBtvFu7APi9pVFVDt-WE7028r1nMWpvAe5CiYb2tzNgCGlvM09-oxpfdY.vWBKI-boWE1UxgZgSc1K6Q](https://cdn.pepperapps.io/diagnostics-cms/public/60dcbed551c1ff090981ed95?signature=eyJhbGciOiJIc2kiLCJlbmMiOiJBMTI4Q0JDLUhTMjU2In0..9nFGX43vdCD-Qd2XE-NzdA.e5mgnWdULSy2PGkSwfQ10kEG1UQzLUxIzkdUvU7F1xv06WNo-c47joEI46OgfiQdEoako-TvRI4CwkLYtVIVYRR7v2jcgknBx9SFQIzw-nqvFqHkx_WlydBAcl4ZA_wEKCPydLqBtvFu7APi9pVFVDt-WE7028r1nMWpvAe5CiYb2tzNgCGlvM09-oxpfdY.vWBKI-boWE1UxgZgSc1K6Q) (3 April  
339 2022, date last accessed).

- 341 14- Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and  
342 asymptomatic SARS-CoV-2 infection. *Nature medicine* 2021; 10.1038/s41591-021-01540-1.  
343 Advance online publication. <https://doi.org/10.1038/s41591-021-01540-1>.
- 344 15- Beilhack G, Monteforte R, Frommlet F, et al. Antibody Response and Safety After  
345 mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort. *Front*  
346 *Immunol* 2021; 12: 780594. doi: 10.3389/fimmu.2021.780594. PMID: 34925359.
- 347 16- Rosa-Diez G, Papaginovic Leiva MM, Lombi F, et al. Safety and Effectiveness of  
348 COVID-19 SPUTNIK V Vaccine in Dialysis Patients. *MedRxiv*. doi:  
349 <https://doi.org/10.1101/2021.10.21.21265349>
- 350 17- Grupper A, Sharon N, Finn T, et al. Humoral Response to the Pfizer BNT162b2 Vaccine  
351 in Patients Undergoing Maintenance Hemodialysis. *Clin J Am Soc Nephrol* 2021; 16 (7): 1037–  
352 42. doi: 10.2215/CJN.03500321.
- 353 18- Yau K, Abe KT, Naimark D, et al. Evaluation of the SARS-CoV-2 Antibody Response to  
354 the BNT162b2 Vaccine in Patients Undergoing Hemodialysis. *JAMA Netw Open* 2021; 4:  
355 e2123622. doi: 10.1001/jamanetworkopen.2021.23622.
- 356 19- Anand S, Montez-Rath M, Han J, et al. Antibody Response to COVID-19 Vaccination in  
357 Patients Receiving Dialysis. *J Am Soc Nephrol* 2021; 32(10):2435–8. doi:  
358 10.1101/2021.05.06.21256768.
- 359 20- Chan L, Fuca N, Zeldis E, et al. Antibody Response to mRNA-1273 SARS-CoV-2  
360 Vaccine in Hemodialysis Patients With and Without Prior COVID-19. *Clin J Am Soc Nephrol*  
361 2021; 16:1258–60. doi: 10.2215/CJN.04080321.
- 362 21- Ionita C, Marcelli D, Nita C, et al. Comparison of antibody response to two different  
363 mRNA Covid-19 vaccines in patients on hemodialysis. *J Nephrol* 2022; 35 (1): 143-151. doi:  
364 10.1007/s40620-021-01195-8. PMID: 34978050.

- 365 22- Pozzetto B, Legros V, Djebali S et al. Immunogenicity and efficacy of heterologous  
366 ChadOx1/BNT162b2 vaccination. *Nature* 2021, 10.1038/s41586-021-04120-y. Advance online  
367 publication. <https://doi.org/10.1038/s41586-021-04120-y>
- 368 23- Schmidt T, Klemis V, Schub D, et al. Immunogenicity and reactogenicity of heterologous  
369 ChAdOx1 nCoV-19/mRNA vaccination. *Nat Med* 2021a; 27 (9), 1530–1535.  
370 <https://doi.org/10.1038/s41591-021-01464-w>
- 371 24- Fiolet T, Kherabi Y, MacDonald CJ, et al. Comparing COVID-19 vaccines for their  
372 characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A  
373 narrative review. *Clin Microbiol Infect* 2021, S1198-743X (21)00604-2.  
374 <https://doi.org/10.1016/j.cmi.2021.10.005>
- 375 25- Mahallawi WH, Ibrahim NA, Mumena WA. Effectiveness of COVID-19 Vaccines in  
376 Patients Under Maintenance Hemodialysis. *Risk Manag Healthc Policy* 2021; 14: 5081-5088.  
377 doi: 10.2147/RMHP.S345686.PMID: 35002344.
- 378 26- Macchia A, Ferrante D, Bouzas MB, et al. Immunogenicity induced by the use of  
379 alternative vaccine platforms to deal with vaccine shortages in a low- to middle-income country:  
380 Results of two randomized clinical trials. *Lancet Reg Health Am.* 2022; 9: 100196. doi:  
381 10.1016/j.lana.2022.100196.PMID:35128512
- 382 27- Schmidt T, Klemis V, Schub D, et al. Cellular immunity predominates over humoral  
383 immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine  
384 regimens in solid organ transplant recipients. *Am J transplant* 2021b, 10.1111/ajt.16818.  
385 <https://doi.org/10.1111/ajt.16818>.
- 386 28- Yen CC, Lin SY, Chen SC, et al. COVID 19 Vaccines in Patients with Maintenance  
387 Hemodialysis. *J Pers Med* 2021;11(8):789. doi: 10.3390/jpm11080789.PMID: 34442432.
- 388 29- Claro F, Silva D, Rodriguez M, et al. Immunoglobulin G antibody response to the Sputnik  
389 V vaccine: previous SARS-CoV-2 seropositive individuals may need just one vaccine dose. *Int j*  
390 *Inf Dis* 2021. 111, 261–266. <https://doi.org/10.1016/j.ijid.2021.07.070>

- 391 30- Rovere P, Laurelli A, Diaz A, et al. Seroprevalence of anti S1 SARS-CoV-2 antibodies in  
392 workers vaccinated with Sputnik V at a public hospital in Buenos Aires. *Medicina (B Aires)* 2021,  
393 81 (6):895-901.
- 394 31- Babamahmoodi F, Saeedi M, Alizadeh-Navaei R, et al. Side effects and Immunogenicity  
395 following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran.  
396 *Scientific reports* 2021; 11(1), 21464. <https://doi.org/10.1038/s41598-021-00963-7>
- 397 32- Wheeler SE, Shurin GV, Yost M, et al. Differential Antibody Response to mRNA COVID-  
398 19 Vaccines in Healthy Subjects. *Microbiology spectrum* 2021; 9 (1), e0034121.  
399 <https://doi.org/10.1128/Spectrum.00341-21>
- 400 33- Steensels D, Pierlet N, Penders J, et al. Comparison of SARS-CoV-2 Antibody  
401 Response Following Vaccination With BNT162b2 and mRNA-1273. *JAMA* 2021; 326(15),  
402 1533–1535. <https://doi.org/10.1001/jama.2021.15125>
- 403 34- Yang HS, Costa V, Racine-Brzostek SE, et al. Association of Age With SARS-CoV-2  
404 Antibody Response. *JAMA network open* 2021; 4 (3), e214302.  
405 <https://doi.org/10.1001/jamanetworkopen.2021.4302>
- 406 35- Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA  
407 vaccine in individuals previously infected with SARS-CoV-2. *Nat Med* 2021; 27(6), 981–984.  
408 <https://doi.org/10.1038/s41591-021-01325-6>
- 409 36- Rodriguez-Espinosa D, Broseta JJ, Maduell F, et al. Humoral Response of the mRNA-  
410 1273 SARS-CoV-2 Vaccine in Peritoneal Dialysis Patients. *Kidney Int* 2021; 100:476–7. doi:  
411 10.1016/j.kint. 2021.05.018.
- 412 37- Tylicki L, Piotrowska M, Biedunkiewicz B, et al. Humoral Response to COVID-19  
413 Vaccination in Patients Treated With Peritoneal Dialysis: The COViNEPH Project. *Pol Arch*  
414 *Intern Med* 2021; 131(10). doi: 10.20452/pamw.16091

- 415 38- Agur T, Ben-Dor N, Goldman S, et al. Antibody Response to mRNA SARS-CoV-2  
416 Vaccine Among Dialysis Patients - A Prospective cohort Study. *Nephrol Dial Transplant* 2021;  
417 gfab155. doi: 10.1093/ndt/gfab155.
- 418 39- Polewska K, Tylicki P, Biedunkiewicz B, et al. Safety and Tolerability of the BNT162b2  
419 mRNA COVID-19 Vaccine in Dialyzed Patients. *COViNEPH Project. Medicina (Kaunas)* 2021;  
420 57(7): 732. doi: 10.3390/medicina57070732.PMID: 34357013.
- 421 40- Powell AA, Power L, Westrop S, et al. Real-world data shows increased reactogenicity in  
422 adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-  
423 June 2021, England. *Euro surveillance: bulletin Europeen sur les maladies transmissibles =*  
424 *European communicable disease bulletin*, 2021 26 (28), 2100634. [https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2021.26.28.2100634)  
425 [7917.ES.2021.26.28.2100634](https://doi.org/10.2807/1560-7917.ES.2021.26.28.2100634)
- 426 41- Haase M, Lesny P, Anderson M, et al. Humoral immunogenicity and tolerability of  
427 heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2  
428 vaccination in hemodialysis patients: A multicenter prospective observational study. *J Nephrol.*  
429 2022: 1-12. doi: 10.1007/s40620-022-01247-7. PMID: 35084719.
- 430 42- Nachtigall I, Bonsignore M, Hohenstein S, et al. Effect of gender, age and vaccine on  
431 reactogenicity and incapacity to work after COVID-19 vaccination: a survey among health care  
432 workers. *BMC Infect Dis* 2022; 22 (1): 291. doi: 10.1186/s12879-022-07284-8.PMID: 35346089.

433 **TABLES**

434 **Table 1. Population epidemiological characteristics (n=107).**

<b>Characteristic</b>	<b>Total, n=107</b>
Age* (years)	64 (50-75)
Male gender, n (%)	79 (73.8)
Primary kidney diseases	
Diabetes, n (%)	15 (14)
High blood pressure, n (%)	13 (12.1)
Polycystic kidney disease, n (%)	8 (7.5)
Glomerular diseases, n (%)	10 (9.3)
Other, n (%)	23 (21.5)
Unknown, n (%)	38 (35.6)
Time on dialysis* (years)	4 (2-7)
Weekly total Kt/V median*	1.5 (1.3-1.9)
Laboratory	
Hemoglobin* (g/dL)	10.8 (9.7-11.6)
Albumin* (g/L)	4.1 (3.7-4.3)
C-reactive protein* (mg/dL)	4.6 (1.4-10.0)
Transferrin saturation*	28 (23-36)
Body mass index (BMI)* (kg/m <sup>2</sup> )	25.3 (22.4-27.9)
Obesity (BMI >30 kg/m <sup>2</sup> )	13 (12.1)

435 \*Median (interquartile range).

436

437 **Table 2. Anti-S-RBD IgG and PROT-80 according to epidemiological and vaccination-**  
 438 **specific parameters (N=107)**

Parameter	Anti-S-RBD			PROT-80	
	N	(BAU/mL)*	<i>p</i>	N (%)	<i>p</i>
<b>Age</b>					
30-49 years	25	605 (285-1396)		17 (68.0%)	
50-60 years	19	501 (88-914)		7 (36.8%)	
>60 years	63	342 (100-2873)	0.770	29 (46%)	0.084
<b>Gender</b>					
Female	28	431 (105-2419)		14 (50.0%)	
Male	79	502 (110-1740)	0.859	39 (49.4%)	0.954
<b>Time on dialysis</b>					
≤3 years	42	345 (100-1551)		18 (42.8)	
≥4 years	65	555 (112-2634)	0.346	35 (53.8)	0.267
<b>Vaccination scheme</b>					
SpV/SpV	84	447 (100-1442)		38 (45.2%)	
SpV/Mod	23	1222 (288-5680)	0.022	15 (65.2%)	0.090
<b>Prior SARS-CoV-2 infection</b>					
No	84	339 (99-911)		35 (41.7%)	
Yes	23	2872 (508-5680)	<0.001	18 (78.3%)	0.002
<b>ΔP-B</b>					
3-10 weeks	19	288 (94-612)		7 (36.8%)	
11-18 weeks	88	518 (117-2761)	0.141	46 (52.3%)	0.312
<b>ΔB-antiSRBD</b>					
3-4 weeks	51	443 (114-1303)		23 (45.1%)	

---

5-8 weeks	41	584 (105-3852)		24 (58.5%)	
9-12 weeks	9	502 (126-2436)		4 (44.4%)	
13-16 weeks	6	120 (53-608)	0.187	2 (33.3%)	0.484

---

439 SpV = Sputnik V, Mod = Moderna

440 \*Median (interquartile range); time intervals from prime to boost ( $\Delta P$ -B) and from boost to anti-

441 S-RBD IgG determination ( $\Delta B$ -antiSRBD).


442 Weekly total Kt/V median, Hemoglobin, Albumin, C-reactive protein, Transferrin saturation, and

443 Body mass index showed no association with Anti-S-RBD or PROT-80.

444

445 **FIGURE**

446 **Figure 1.** Anti-S-RBD IgG levels for homologous (SpV/SpV) and heterologous (SpV/Mod)  
447 vaccination schemes in subjects who had (A) or had not (B) a confirmed SARS-CoV-2 infection  
448 prior to immunization.



449

450

451

452

453

454

455

456

457

458


459

460

461


462

463 **Figure 2.** Reactogenicity: frequency of local and systemic adverse effects as reported by the  
464 participants for the homologous (SpV/SpV) and heterologous (SpV/Mod) schemes, classified by  
465 severity.




466


### SpV/MOD




### SpV/SpV




**Pain at the injection site**




**Fatigue**



**Fever**



**Myalgia**



Sputnik-V/Sputnik-V



Sputnik-V/Moderna

